HC Wainwright Issues Optimistic Outlook for DAWN Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Day One Biopharmaceuticals from ($0.30) to ($0.27) per share and maintains a "Buy" rating with a target price of $25.00.
• Day One Biopharmaceuticals reported a Q2 loss of ($0.29) per share, beating analyst expectations of ($0.35), and had revenues of $33.91 million, falling short of the $35.55 million consensus estimate.
• Insider selling has occurred recently, with General Counsel and CFO both reducing their holdings, amid reports that institutional investors, like FMR LLC, have increased their stakes in the company.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Wednesday, August 6th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.27) for the quarter, up from their previous forecast of ($0.30). HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $0.51 EPS and FY2029 earnings at $1.01 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%. The firm had revenue of $33.91 million for the quarter, compared to the consensus estimate of $35.55 million.

Other equities analysts have also recently issued reports about the stock. Wedbush reaffirmed an "outperform" rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC reduced their price objective on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $25.33.

Day One Biopharmaceuticals Stock Performance

DAWN traded up $0.07 during trading on Friday, reaching $6.10. 2,121,852 shares of the stock were exchanged, compared to its average volume of 2,009,409. The stock has a market cap of $624.82 million, a P/E ratio of -6.42 and a beta of -1.26. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $16.76. The stock's 50 day moving average price is $6.70 and its two-hundred day moving average price is $8.02.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in DAWN. Creative Planning purchased a new position in Day One Biopharmaceuticals during the 2nd quarter valued at about $120,000. Police & Firemen s Retirement System of New Jersey increased its stake in Day One Biopharmaceuticals by 41.1% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 17,701 shares of the company's stock worth $115,000 after purchasing an additional 5,152 shares during the period. Geode Capital Management LLC increased its stake in shares of Day One Biopharmaceuticals by 11.2% during the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company's stock valued at $11,132,000 after buying an additional 171,964 shares during the period. ProShare Advisors LLC grew its stake in Day One Biopharmaceuticals by 12.9% in the second quarter. ProShare Advisors LLC now owns 18,545 shares of the company's stock worth $121,000 after purchasing an additional 2,121 shares during the period. Finally, Los Angeles Capital Management LLC boosted its holdings in Day One Biopharmaceuticals by 49.8% in the second quarter. Los Angeles Capital Management LLC now owns 82,257 shares of the company's stock worth $535,000 after acquiring an additional 27,335 shares in the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Charles N. York II sold 4,282 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the completion of the sale, the chief financial officer directly owned 265,231 shares of the company's stock, valued at approximately $1,660,346.06. This represents a 1.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeremy Bender sold 13,964 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $87,414.64. Following the completion of the sale, the chief executive officer directly owned 145,737 shares of the company's stock, valued at $912,313.62. The trade was a 8.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,725 shares of company stock worth $167,299. Corporate insiders own 6.20% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.